Tveit, K. M., Guren, T., Glimelius, B., Pfeiffer, P., Sorbye, H., Pyrhonen, S., Sigurdsson, F., Kure, E., Ikdahl, T., Skovlund, E., Fokstuen, T.
, Hansen, F., Hofsli, E., Birkemeyer, E., Johnsson, A., Starkhammar, H.
, Yilmaz, M. K., Keldsen, N., Erdal, A. B. ... Christoffersen, T. (2012).
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study.
Journal of Clinical Oncology,
30(15), 1755-62.
https://doi.org/10.1200/JCO.2011.38.0915
Visco, C., Li, Y., Xu-Monette, Z. Y., Miranda, R. N., Green, T. M., Li, Y., Tzankov, A., Wen, W., Liu, W.-M., Kahl, B. S., d'Amore, E. S. G., Montes-Moreno, S.
, Dybkær, K., Chiu, A., Tam, W., Orazi, A., Zu, Y., Bhagat, G., Winter, J. N. ... Young, K. H. (2012).
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP consortium program study.
Leukemia,
26(9), 2103-13.
https://doi.org/10.1038/leu.2012.83